Biogen Inc. reports results for the quarter ended September 30 - Earnings Summary

Biogen

28/10/2026 13:32

Biogen Inc. BIIB.OQ reported quarterly adjusted earnings of $2.62​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $4.81.  The mean expectation of twenty nine analysts for the quarter was for earnings of $1.99 per share. Wall Street expected results to range from $1.44  to $2.31 per share.
Revenue rose 10.6% to $2.80 billion from a year ago; analysts expected $2.63 billion. 
Biogen Inc.'s reported EPS for the quarter was a loss of 14 cents​.
The company reported a quarterly loss of $20.6 million.
Biogen Inc. shares had risen by 11.9% this quarter and gained 43.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 13.2% in the last three months.​ 
In the last 30 days, nine analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy," 11 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Biogen Inc. is $248.00, about 1.9% below its last closing price of $252.73
This summary was machine generated from LSEG data October 28 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
1.99
2.62
Beat
Jun. 30 2026 
2.95
3.60
Beat
Mar. 31 2026 
2.77
3.57
Beat
Dec. 31 2025 
1.61
1.99
Beat